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Background: Tuberculosis (TB) caused by Mycobacterium tuberculosis is the leading cause of death from a bacterial
infection. The 4-aminopiperidine (PIP) series has been reported as having anti-bacterial activity against M. tuberculosis.
We explored this series for its potential to inhibit aerobic growth of M. tuberculosis. We examined substitution at the
N-1 position and C-4 position of the piperidine and modifications of the piperidine moiety systematically to delineate
structure-activity relationships influencing potency. Compounds were tested for growth-inhibitory activity against
virulent M. tuberculosis. A selected set of compounds were also tested for its activity against Staphylococcus aureus.
Results: The compound with a norbornenylmethyl substituent at the N-1 position and N-benzyl-N-phenethylamine at
the C-4 position of the piperidine (1) was the only active compound with a minimum inhibitory concentration (MIC) of
10 μM against M. tuberculosis. Compounds were not active against S. aureus.
Conclusions: We were unable to derive any other analogs with MIC < 20 μM against M. tuberculosis. Therefore we
conclude that the lack of activity is a liability in this series precluding it from further development.
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Tuberculosis (TB) caused by Mycobacterium tuberculosis
is the leading cause of death from a bacterial infection.
In 2010, according to the World Health Organization
(WHO), 8.8 million new cases and 1.4 million deaths
from the disease were reported [1]. In addition, more
than 2 billion people globally are infected. Of these indi-
viduals with latent infection, approximately 10% are ex-
pected to develop active TB in their life [2]. Currently
the recommended first-line TB treatment regimens re-
quire a minimum of 6 months of multidrug therapy,
resulting in challenges with patient adherence. The
result of inadequate therapy and poor compliance has
contributed to a rise in the emergence of multidrug resist-
ant (MDR) and extensively drug-resistant (XDR) strains of
M. tuberculosis [2-6]. Hence, there is an urgent need to* Correspondence: Joshua.Odingo@idri.org
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article, unless otherwise stated.develop novel anti-TB drugs that are effective against both
drug sensitive and resistant M. tuberculosis [2].
The 4-aminopiperidine (PIP) series was reported as a
new class of compounds with activity against M. tuber-
culosis in a high-throughput cell-based assay [7]. Of the
14 compounds reported, 4 gave > 90% inhibition of
growth in a single point assay at 10 μg/mL. All of these ac-
tives were N-benzyl-N-phenethyl-1-arylpiperidin-4-amines.
As a part of our ongoing TB drug discovery program, we
were interested in exploring the potential of the PIP series
to be developed as a lead series for tuberculosis treatment.
We conducted an exploratory structure-activity relationship
study to evaluate the series for their activity against M. tu-
berculosis as well as against staphylococcus aureus. We
tested compound cytotoxicity (TC50) against eukaryotic
cells using the Vero cell line (derived from African green
monkey kidney cells).Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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We investigated the activity of the series against a virulent
strain of M. tuberculosis in liquid culture under aerobic
growth conditions [8]. First, we probed the consequences
of varying the type of substituents at N-1 position of com-
pound a, while the substituent at the C-4 position was
kept constant. Only the compound with the norbornenyl-
methyl substituent at N-1 position (1) showed good activ-
ity with a minimum inhibitory concentration (MIC)
against M. tuberculosis of 10 μM (Table 1) and is similar
to what has been previously reported (4 μM) [7]. However
its activity against Staphylococcus aureus was > 200 μM.Table 1 Activity of N-substituted analogs of the PIP series ag












aMtb. MIC is the minimum concentration required to inhibit growth of M. tuberculo
experiments; b% inhibition of growth at 20 μM for compounds with MIC >20 μM.
ND: not determined; cTC50 is the concentration required to inhibit growth of Vero cThe N-1 substituents comprising of aromatic, hetero-
aromatic and aliphatic groups were all linked to the piperi-
dine via a methylene spacer. The aromatic substituents we
tested include benzyl groups with an electron withdrawing
Br group (8) and electron donating OMe group. The ali-
phatics had an acyclic ethyl group (7) and a cyclic cyclo-
pentyl group (10). The heteroaromatics consisted of two
isomeric pyridyl compounds (4, 5) and an indole (3). All
these piperidine compounds had the same substituent at
the C-4 position, which is N-(2-phenethyl)-N-(benzyl).
Alternative substituents at N-1 position as replacement
for norbornenylmethyl group gave no improvement onainst M. tuberculosis
% Ib TC50












sis completely in liquid culture. MIC is the average of two independent
ell line by 50%. TC50 is the average of two independent experiments.
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had MICs above 20 μM, except an indole derivative (3),
with an MIC of 20 μM. The benzyl derivative (6) also
showed some activity achieving >70% inhibition of Mtb.
growth at 20 μM with all other compounds demonstrating
no activity (<30% inhibition of growth at 20 μM). Com-
pounds 3 and 9 had previously been reported as having
anti-tubercular activity with MIC of 9.4 μM and 7.4 μM
respectively [7]. However, in our assay the MICs were
20 μM and > 20 μM respectively (Table 1). None of the
compounds showed any activity against S. aureus.
We then investigated the effect of having a broad range
of substitutions at the C-4 position of the piperidine ringTable 2 Activity of piperidine analogs with a carbonyl group












aMtb. MIC is the minimum concentration required to inhibit growth of M. tuberculo
experiments; b% inhibition of growth at 20 μM for compounds with MIC >20 μM.
ND: not determined; cTC50 is the concentration required to inhibit growth of Vero cand piperidine replacements. The biological activity was
determined, but none of the compounds were active, with
no inhibition, even at 20 μM (Table 2). The replacement
of the phenethyl group in compound 1 by ethyl (22) re-
sulted in complete loss of activity, indicating a require-
ment for flexible hydrophobic group at this position.
Similarly, other replacements of the N-phenethyl-N-ben-
zylamine we tried had a negative impact on the biological
activity. In addition we investigated effect of change from
piperidine to piperazine or morpholine scaffold. However,
all these changes were detrimental to anti TB activity of
these compounds. Again, none of the compounds showed
any activity against staphylococcus aureus.of the PIP series against M. tuberculosis
% Ib TC50
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ing methylene spacer with an amide as in compound 23.
Similar amides with different substitutions at the N-1 pos-
ition and N-4 position are shown on Table 3. Despite the
significant changes made at the methylene group and N-1
and N-4 substitutions, there was no improvement in anti-
tubercular activity noted (MIC > 20 μM).
Conclusions
We conducted a systematic exploration of the 4-
aminopiperidine compound series for its inhibitory ac-
tivity against M. tuberculosis. The compound with a nor-
bornenylmethylene substituent at the N-1 position and
N-phenethyl-N-benzyl at the C-4 position of the piperi-
dine (1) is a singleton, with a minimum inhibitory con-
centration (MIC) of 10 μM against M. tuberculosis. All
the compounds were inactive against S. aureus. We were
unable to improve the activity in this series, even after











aMtb. MIC is the minimum concentration required to inhibit growth of M. tuberculo
experiments; b% inhibition of growth at 20 μM for compounds with MIC >20 μM. N
Vero cell line by 50%. TC50 is the average of two independent experiments.On this basis we concluded that the series lacks further
potential for drug development.
Methods
Determination of minimum inhibitory concentration
against M. tuberculosis (MIC)
MICs were run as described in [8]; briefly MICs were
determined against M. tuberculosis H37Rv grown in
Middlebrook 7H9 medium containing 10% OADC (oleic
acid, albumin, dextrose, catalase) supplement (Becton
Dickinson) and 0.05% w/v Tween 80 (7H9-Tw-OADC)
under aerobic conditions. Bacterial growth was mea-
sured by OD after 5 days of incubation at 37°C. The
MIC was defined as the minimum concentration re-
quired for complete inhibition of growth.
Eukaryotic cytotoxicity assay
Cytotoxicity was determined against the Vero African
green monkey kidney cell line (ATCC CCL-81). Cellsf the PIP series against M. tuberculosis and
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(DMEM), High Glucose, GlutaMAX™ (Invitrogen), 10%
FBS (Fetal Bovine Serum), and 1x of Penicillin-
Streptomycin Solution (100 units/mL of penicillin,
100 μg/mL of streptomycin). Compounds were solubi-
lized in DMSO (dimethyl sulfoxide) and assayed using a
10-point three-fold serial dilution starting at the highest
concentration of 50 μM. CellTiter-Glo® Reagent (Promega)
was added to 96-well plates after 2 days of incubation at
37°C, 5% CO2. Relative luminescent units (RLU) were
measured using Perkin Elmer Wallac 1420 Victor2 plate
reader. Inhibition curves were fitted using the Levenberg–
Marquardt algorithm. Toxic concentration (TC50) was
defined as the concentration of compound that gave 50%
inhibition of growth.
Determination of activity against Staphylococcus aureus
S. aureus ATCC 25923 strain was grown in Mueller
Hinton II broth at 35°C overnight. The overnight culture
was diluted in fresh broth and used as inoculum for the
antimicrobial screen. Working stocks (50X) of test com-
pounds were prepared in DMSO. Each well of the 384-
well plate contained 30 μl of the inoculum and 0.6 μl of
the 50X compound working stock. Plates were incubated
at 35°C for 18 hours and 30 μl of the BacTiter-Glo™ re-
agent (Promega) was added. Relative luminescent units
(RLU) were measured using and normalized to growth
control wells (2% DMSO) and expressed as % Growth.
IC50 values were calculated using the Levenberg–Mar-
quardt nonlinear regression algorithm and defined as
the compound concentration that produced 50% of the
growth inhibitory response. The IC90 value was defined
as the compound concentration that produced 90% of
the growth inhibitory response [9,10].
Compound purity analysis
HPLC analysis was conducted on an Agilent 1100 series LC
system (Agilent ChemStation Rev.A.10.02; Phenomenex-
Luna-C18, 4.8 mm× 150 mm, 5 μm, 1.0 mL/min, UV
254 nm, 214 nm, room temperature) with MeCN/H2O
(0.05% TFA or HCOOH buffer) gradient elution. HPLC-
MS was performed on a Gilson 321 HPLC with detection
performed by a Gilson 170 DAD and a Finnigan AQA mass
spectrometer operating in electrospray ionization mode
using a Phenomenex Gemini C18 150 × 4.6 mm column.
All the compounds were purchased from ChemBridge
Corporation. Purity was calculated from the LC trace at
214 nm.
1: LC-MS (ESI) m/z: 401.1 (M +H)+, tR = 0.76 min,
purity >99%.
2: LC-MS (ESI) m/z: 294.9 (M +H)+, tR = 0.64 min,
purity >99%.
3: LC-MS (ESI) m/z: 423.9 (M +H)+, tR = 0.79 min,
purity >99%.4: LC-MS (ESI) m/z: 385.9 (M +H)+, tR = 0.74 min,
purity >99%.
5: LC-MS (ESI) m/z: 385.9 (M +H)+, tR = 0.73 min,
purity >99%.
7: LC-MS (ESI) m/z: 323.00 (M +H)+, tR = 0.70 min,
purity >99%.
8: LC-MS (ESI) m/z: 464.8 (M +H)+, tR = 3.53 min,
purity >99%.
9: LC-MS (ESI) m/z: 444.9 (M +H)+, tR = 2.79 min,
purity >99%.
10: LC-MS (ESI) m/z: 363.00 (M +H)+, tR = 0.71 min,
purity >99%.
11: LC-MS (ESI) m/z: 434.9 (M +H)+, tR = 4.57 min,
purity >99%.
12: LC-MS (ESI) m/z: 284.00 (M +H)+, tR = 0.55 min,
purity >99%.
13: LC-MS (ESI) m/z: 271.00 (M +H)+, tR = 0.73 min,
purity >99%.
15: LC-MS (ESI) m/z: 194.00 (M +H)+, tR = 0.66 min,
purity >99%.
16: LC-MS (ESI) m/z: 269.00 (M +H)+, tR = 0.74 min,
purity >99%.
17: LC-MS (ESI) m/z: 275.00 (M +H)+, tR = 0.54 min,
purity >99%.
18: LC-MS (ESI) m/z: 366.00 (M +H)+, tR = 0.67 min,
purity >99%.
19: LC-MS (ESI) m/z: 208.00 (M +H)+, tR = 0.66 min,
purity >99%.
20: LC-MS (ESI) m/z: 235.0 (M +H)+, tR = 0.69 min,
purity >99%.
21: LC-MS (ESI) m/z: 235.00 (M +H)+, tR = 0.66 min,
purity >99%.
23: LC-MS (ESI) m/z: 398.9 (M +H)+, tR = 4.21 min,
purity >99%.
24: LC-MS (ESI) m/z: 404.9 (M +H)+, tR = 4.12 min,
purity >99%.
25: LC-MS (ESI) m/z: 413.9 (M +H)+, tR = 4.21 min,
purity >99%.
26: LC-MS (ESI) m/z: 413.9 (M +H)+, tR = 3.99 min,
purity >99%.
27: LC-MS (ESI) m/z: 456.9 (M +H)+, tR = 4.53 min,
purity >99%.
28: LC-MS (ESI) m/z: 432.9 (M +H)+, tR = 4.63 min,
purity >99%.
29: LC-MS (ESI) m/z: 351.00 (M +H)+, tR = 0.71 min,
purity >99%.
30: LC-MS (ESI) m/z: 323.9 (M +H)+, tR = 0.71 min,
purity >99%.Abbreviations
TB: Tuberculosis; PIP: 4-aminopiperidine; MIC: Minimum inhibitory concentration.Competing interests
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